BCD-100
Sponsors
Biocad
Conditions
Cervical CancerCervical Cancer MetastaticCervical Cancer RecurrentLung CancerMelanomaMelanoma (Skin)Melanoma AdvancedMelanoma Metastatic
Phase 1
Phase 2
International Trial of the Efficacy and Safety of BCD-100 in Patients With Melanoma
NCT03269565
Start: 2017-08-31End: 2021-01-31Updated: 2020-09-18
Efficacy, Safety and Pharmacokinetics of BCD-100 (Anti-PD-1) Monotherapy as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (DOMINUS)
NCT03288870
Start: 2017-09-19End: 2021-08-10Target: 218Updated: 2020-10-29
Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer (CAESURA)
NCT03912402
Start: 2018-12-25End: 2020-07-07Target: 49Updated: 2019-05-09
Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma
NCT03913923
Start: 2019-07-01End: 2023-12-31Updated: 2023-02-10
Phase 3
Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy as First Line Treatment in Patients With Advanced Non-Squamous NSCLC
NCT03912389
Start: 2019-06-01End: 2023-12-31Target: 292Updated: 2020-09-17
Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy With and Without Bevacizumab as First-Line Treatment of Subjects With Advanced Cervical Cancer (FERMATA)
NCT03912415
Start: 2019-10-01End: 2024-12-01Target: 316Updated: 2020-09-18
A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma
Active, not recruitingNCT05732805
Start: 2022-08-02End: 2025-07-31Target: 270Updated: 2025-02-27